---
title: "Citi Sticks to Its Buy Rating for Royalty Pharma (RPRX)"
description: "According to TipRanks, Meacham is a 4-star analyst with an average return of 4.2% and a 55.14% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260882069.md"
published_at: "2025-10-13T10:55:55.000Z"
---

# Citi Sticks to Its Buy Rating for Royalty Pharma (RPRX)

> According to TipRanks, Meacham is a 4-star analyst with an average return of 4.2% and a 55.14% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Royalty Pharma with a $43.50 average price target, a 20.80% upside from current levels. In a report released on October 10, Morgan Stanley also maintained a Buy rating on the stock with a $54.00 price target.

According to TipRanks, Meacham is a 4-star analyst with an average return of 4.2% and a 55.14% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Royalty Pharma with a $43.50 average price target, a 20.80% upside from current levels. In a report released on October 10, Morgan Stanley also maintained a Buy rating on the stock with a $54.00 price target.

### Related Stocks

- [RPRX.US - Royalty Pharma PLC - CL](https://longbridge.com/en/quote/RPRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| What to expect from Royalty Pharma’s (RPRX) Q4 earnings | Royalty Pharma (NASDAQ:RPRX) is set to report its Q4 earnings this Wednesday. In the previous quarter, the company misse | [Link](https://longbridge.com/en/news/275397167.md) |
| Citi Sticks to Their Buy Rating for Royalty Pharma (RPRX) | Citi analyst Geoff Meacham has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $48.00. Meacham,  | [Link](https://longbridge.com/en/news/271828597.md) |
| Otsuka Weighs Investment Unit Cut to Attract Individual Investors | Otsuka Holdings Co is considering reducing its investment unit to enhance share accessibility for individual investors a | [Link](https://longbridge.com/en/news/275851061.md) |
| REG - Rubric Capital Mgmt Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc | Rubric Capital Management LP disclosed its position in Avadel Pharmaceuticals plc under Rule 8.3 of the Irish Takeover P | [Link](https://longbridge.com/en/news/275770954.md) |
| BridgeBio Pharma (BBIO) Receives a Buy from TD Cowen | TD Cowen analyst Tyler Van Buren has maintained a Buy rating on BridgeBio Pharma (BBIO) with a price target of $95.00. V | [Link](https://longbridge.com/en/news/275790948.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.